Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Pavletic, Steven  [Clear All Filters]
Journal Article
Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, et al. Failure-free Survival in a Prospective Cohort of Patients with Chronic Graft-Versus-Host Disease. Haematologica. 2015.
Sabile J, Pavletic S, Migdady Y. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions. Cancer J. 2023;29(3):179-187.
Fowler DH, Mossoba ME, Halverson DC, Kurlander R, Schuver BBlacklock, Carpenter AE, Hansen B, Steinberg SM, Ali SAbbas, Tageja N, et al. High-Dose Sirolimus And Immune Selective Pentostatin Plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-Versus-Tumor Responses. Clin Cancer Res. 2015.
Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers MED, Cutler C, Jagasia M, Gooley T, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021.
Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2018.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.